NRX Pharmaceuticals, Inc. (NRXP) - Dilution Analysis

10-Q filing | 32.3M shares outstanding

S-3/A filing: The filing is an S-3/A registration statement for a shelf offering of up to $150 million of various securities, including common stock, preferred stock, debt securities, depositary shares, warrants, rights, purchase contracts, or units, or any combination thereof.

10-Q filing | 27.7M shares outstanding

10-Q filing | 17.9M shares outstanding

RW filing: NRx Pharmaceuticals, Inc. requests the withdrawal of its Registration Statement on Form S-1 (File No. 333-283220) and will not pursue the public offering at this time.

S-3 filing: NRx Pharmaceuticals files an S-3 shelf registration to offer and sell up to $150 million of common stock, preferred stock, debt securities, depositary shares, warrants, rights, purchase contracts or units, or any combination thereof.

10-Q filing | 16.4M shares outstanding

10-K filing | 14.6M shares outstanding

8-K filing: NRX Pharmaceuticals, Inc. entered into a Second Amended and Restated Securities Purchase Agreement with an accredited investor to sell 732,600 shares of common stock at a price of $2.73 per share. ($2.0M proceeds)

8-K filing: NRx Pharmaceuticals, Inc. completed the sale of $5.435 million in Senior Secured Convertible Promissory Notes and Warrants to purchase up to 862,699 shares of Common Stock. Additionally, the company sold 1,215,278 shares of Common Stock at $2.88 per share in a registered direct offering, along with unregistered Common Stock purchase warrants to purchase up to 1,215,278 shares of Common Stock. ($3.5M proceeds)

8-K filing: NRx Pharmaceuticals, Inc. entered into a binding term sheet with JGS Holdings LLC, where the Investor intends to purchase $25.0 million in shares of HOPE's Series A Preferred Stock convertible into one-third of all fully diluted outstanding equity of HOPE and 730,000 shares of the Company's common stock at $2.74 per share for $2.0 million. ($2.0M proceeds)

S-1 filing: This prospectus relates to the resale from time to time of up to 3,304,374 shares of our common stock by the selling stockholders.

10-Q filing | 11.0M shares outstanding

8-K filing: NRx Pharmaceuticals sold $5.435 million in Notes and warrants to purchase up to 1,349,305 shares of Common Stock on the First Closing Date, and $5.435 million in Notes and warrants to purchase up to 1,846,128 shares of Common Stock on the Second Closing Date; the company will not proceed with the third tranche of $5.435 million in Notes under the Purchase Agreement. ($10.0M proceeds)

10-Q filing | 10.5M shares outstanding

8-K filing: NRx Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to sell senior secured convertible promissory notes and warrants for up to approximately $15.0 million, and amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of outstanding shares.

8-K filing: The underwriters exercised their option to purchase an additional 91,050 shares of NRx Pharmaceuticals, Inc.'s common stock at a price of $3.30 per share, closing on May 23, 2024. ($0.3M proceeds)

10-Q filing | 8.9M shares outstanding

8-K filing: NRx Pharmaceuticals, Inc. completed an underwritten public offering of 607,000 shares of common stock at a public offering price of $3.30 per share, resulting in gross proceeds of approximately $2.0 million before deducting underwriting discounts and commissions. ($2.0M proceeds)

8-K filing: Stock split 1-for-10 | Outstanding: 81,946,957 → 9,569,978

10-K filing | 75.8M shares outstanding

8-K filing: NRx Pharmaceuticals, Inc. announces the closing of the underwriters' option exercise to purchase an additional 750,000 shares of common stock at $0.30 per share, completed on March 6, 2024. ($0.23M proceeds)

8-K filing: NRx Pharmaceuticals, Inc. closed a public offering of 5,000,000 shares of common stock at a price of $0.30 per share on February 28, 2024, resulting in gross proceeds of approximately $1.5 million. ($1.5M proceeds)

8-K filing: NRx Pharmaceuticals' subsidiary, NeuroRx, amended its License Agreement with Alvogen, receiving $5 million in advance milestone payment in exchange for issuing 4,195,978 warrants to Alvogen to purchase the company's common stock at a strike price of $0.40.

10-Q filing | 81.9M shares outstanding

8-K filing: The Company issued 3,000,000 shares of Series A Convertible Preferred Stock and 3,000,000 Investor Warrants for aggregate proceeds of approximately $1.2 million before expenses. ($1.2M proceeds)

8-K filing: NRX Pharmaceuticals, Inc. issued 675,676 shares of common stock to GEM Global Yield LLC SCS in a private placement on August 31, 2023, under the terms of a previously disclosed settlement agreement. No proceeds were received by the company in connection with the issuance of the Settlement Shares.

10-Q filing | 73.2M shares outstanding

8-K filing: The company entered into a securities purchase agreement for the issuance and sale of 9,670,002 shares of common stock and warrants to purchase up to 9,670,002 shares of common stock in a registered direct offering for $0.65 per share, with gross proceeds expected to be approximately $6.28 million. ($6.28M proceeds)

10-Q filing | 67.5M shares outstanding

10-K filing | 58.8M shares outstanding

8-K filing: NRx Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of 3,766,666 shares of common stock and warrants to purchase up to 3,766,666 shares of common stock in a registered direct offering priced at $0.75 per share, with gross proceeds expected to be approximately $2.85 million. ($2.85M proceeds)

10-Q filing | 66.4M shares outstanding

10-Q filing | 65.7M shares outstanding

S-3/A filing: This is an S-3/A filing for NRX Pharmaceuticals, Inc. to register securities under the Securities Act of 1933, including exhibits related to underwriting agreements for debt, equity, depositary shares, purchase contracts, and units, as well as legal opinions and consents.

S-3 filing: NRX Pharmaceuticals, Inc. files an S-3 registration statement for the potential offering of common stock, preferred stock, debt securities, depositary shares, warrants, rights, purchase contracts, or units, or any combination thereof, with an aggregate initial offering price of up to $150,000,000.

POS AM filing: This prospectus relates to the primary issuance by NRX Pharmaceuticals, Inc. of up to 14,665,850 shares of common stock and the resale of up to 43,437,808 shares of Common Stock held by certain selling securityholders and selling service providers.

10-Q filing | 63.7M shares outstanding

POS AM filing: This prospectus relates to the resale of common stock by selling securityholders and service providers, as well as the issuance of common stock upon the exercise of investment options.

POS AM filing: This prospectus relates to the resale of up to 8,757,258 shares of common stock by selling securityholders and the issuance of up to 3,586,250 shares of common stock upon the exercise of outstanding warrants.

S-1 filing: NRX Pharmaceuticals is filing an S-1 to register 7,824,727 shares of common stock for resale by selling securityholders, 8,215,963 shares of common stock issuable upon exercise of preferred investment options, and 391,236 shares of common stock issuable upon exercise of placement agent options.

10-K filing | 46.9M shares outstanding

8-K filing: Ira Strassberg was appointed as Chief Financial Officer and Treasurer of NRx Pharmaceuticals, Inc. effective immediately on March 15, 2022. He also received stock options to purchase 425,000 shares of the company's common stock at an exercise price of $3.10 per share.

8-K filing: NRX Pharmaceuticals, Inc. consummated the closing of a private placement issuing 7,824,727 shares of common stock and preferred investment options to purchase up to an aggregate of 7,824,727 shares of common stock at a price of $3.195 per share, resulting in gross proceeds of approximately $25.0 million. ($25.0M proceeds)

10-Q filing | 43.0M shares outstanding

8-K filing: NRX Pharmaceuticals, Inc. entered into a Shareholder Agreement with Shimshon Hen and David Sepiashvili to establish a joint venture, VaccineCo, for the development and commercialization of the BriLifeTM vaccine, and issued 4,000,000 shares of common stock to the Shareholders as consideration for their work as consultants prior to the formation of VaccineCo.

S-1 filing: This S-1 filing relates to the resale of common stock by selling securityholders and service providers, as well as the issuance of common stock upon the exercise of investment options.

8-K filing: NRX Pharmaceuticals, Inc. consummated the closing of a private placement, issuing 2,727,273 shares of common stock at $11.00 per share and investment options to purchase up to 2,727,273 additional shares at $12.00 per share, resulting in gross proceeds of approximately $30.0 million. ($30.0M proceeds)

8-K filing: NRX Pharmaceuticals, Inc. announced a private placement of common stock expected to close on or about August 23, 2021. The Company will issue 2,727,273 shares of common stock and preferred investment options to purchase up to an aggregate of 2,727,273 shares of common stock, each for a purchase price of $11.00, resulting in gross proceeds of approximately $30 million before deducting fees. ($30.0M proceeds)

10-Q filing | 41.7M shares outstanding

S-1/A filing: This S-1/A filing registers 8,757,258 shares of common stock for resale by selling securityholders and 3,586,250 shares of common stock issuable upon exercise of outstanding warrants.

S-1 filing: This S-1 filing is for the registration of 8,757,258 shares of common stock by selling securityholders and 3,586,250 shares of common stock issuable upon exercise of outstanding warrants.

10-Q filing | 2.7M shares outstanding

10-K filing | 2.8M shares outstanding

10-Q filing | 2.7M shares outstanding

10-Q filing | 2.7M shares outstanding

10-Q filing | 2.7M shares outstanding

10-K filing | 2.7M shares outstanding